Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Celyad announces first quarter 2016 business update Significant progress made in NKR-2 trial CHART-1 data readout confirmed end of June 2016 Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today provides an update on key clinical and operational developments over the three-month period ended 31 March 2016. HIGHLIGHTS OF THE FIRST QUARTER ? Infusion and 21 day-safety follow-up of the first patient of the third cohort in NKR-2 Phase I/IIa trial conducted at the Dana Farber Cancer Institute in Boston, USA. ? Strategic partnership with Institut Curie in Paris, France, to further develop the Company’s NKR-T pipeline in cellular immunotherapies for cancer. ? First US patent relating to a method of producing allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR). ? Appointment of 10 leading international immuno-oncology experts to the Company’s Scientific Advisory Board to help guide Celyad’s development of its NKR-T platform. ? Certification for C-Cure® non-clinical data from the European Medicines Agency (EMA) and Notification of the EMA of its intent to submit a MAA for C-Cure®. ? Reinforcement of the corporate management team with the appointment of Pierre Brynaert as Chief Human Resources Officer, Richard Mountfield as VP of Global Regulatory Affairs and Jean-Pierre Latere as VP of Regenerative Medicine and Medical Devices Franchise. Dr. Christian Homsy, Chief Executive Officer of Celyad, commented: “The first quarter of 2016 has been a very productive period for Celyad. We successfully met our operational milestones in our NKR-2 trial and also established some key strategic collaborations and assets as we continue to make progress across our development programs. “We are surrounding ourselves with top international experts and partners to achieve our clinical and business development aims for our novel pipeline, as well as building strong patent portfolios which we believe will position Celyad as a major player in the field of regenerative medicine and immuno-oncology. “We now look forward to the expected announcement of the topline data from our CHART-1 Phase III trial and the safety and feasibility data on the first doses in our NKR-2 Phase I/IIa study at the end of June.” Patrick Jeanmart, Chief Financial Officer of Celyad, added: “We are delighted to report for the first quarter of 2016 a cash position in line with our expectations. We also paid during this first quarter the first clinical development milestones related to our NKR-2 clinical trial, which demonstrates the significant progress made in the clinical development of NKR-2.” OPERATIONAL AND FINANCIAL REVIEW Over the first quarter, Celyad has made significant progress in the preclinical and clinical development of its NKR-T platform. The Company successfully completed the safety follow-up of the patients of the second dose level cohort in NKR-2 T-Cells Phase I/IIa trial, a dose escalation study evaluating the safety and feasibility of the NKG2D receptor in cancer patients suffering from Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM). No dose limiting toxicity was reported of the second dose level. The Company also reported the completion of the 21-day safety follow-up of the first patient enrolled in the third dose level in the Phase I/IIa clinical trial. No treatment related safety issues were reported. In March, the Company strengthened its patent portfolio having been granted, by the U.S. Patent and Trademark Office (USPTO), the first U.S. patent relating to a method of producing allogeneic primary human T cells that are engineered to be T Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR). The first US patent (9,181,527) - that was granted to Celyad in November 2015 - was related to TCR deficient CAR T cells, regardless of the method used to generate them. This new patent fosters Celyad’s coverage for its proprietary CAR T cells by broadly protecting methods for making these modified allogeneic T cells, and providing them as medicines. The resulting products may benefit patients with various human disease conditions, particularly cancer. By reinforcing its patent portfolio in the CAR-T field, Celyad confirms its leadership in engineered cell therapy, and in the allogeneic CAR T space. Celyad also announced a strategic partnership with the Inserm “Cancer and Immunity” Unit of Institut Curie in Paris, France, to further develop its NKR-T pipeline in cellular immunotherapies for cancer. Through this partnership, Celyad and Institut Curie will pool their expertise to progress Celyad’s immuno-oncology pipeline with the aim of bringing novel cellular immunotherapies to cancer patients. The partnership will build on Institut Curie’s first-in-class expertise and state of the art translational, preclinical and clinical know-how in cancer biology and immunology, as well as Celyad’s widely recognized cell therapy and cell manufacturing capabilities. In March, Celyad notified the European Medicines Agency (EMA) of its intent to submit a Market Authorization Application (MAA) for C-Cure® in November 2016. During the first quarter of 2016, Celyad reinforced its management team with the appointment of Pierre Brynaert as Chief Human Resources Officer, Richard Mountfield as Vice President of Global Regulatory Affairs and Jean-Pierre Latere as Vice President of Regenerative Medicine and Medical Devices Franchise. The Company ended the quarter with €94.7 million in cash. Use of cash of the quarter amounts to €12.8 million, of which €7.4 million cash used to finance the operations of the Group. In January, the Company paid its first clinical development milestone ($5.0 million) to Celdara Medical Inc, former owner of the NKR-T technology platform. Investments made in capital expenditures over the quarter amounted to €0.8 million. EVENTS SUBSEQUENT TO QUARTER-END The Company recently reiterated its market guidance regarding the availability of C-Cure® CHART-1 data. CHART-1 data readout in expected by end of June 2016. In April, Celyad received certification for C-Cure non-clinical data from the European Medicines Agency (EMA). This certification is the second of three modules, following the certification of quality data obtained in May 2014, made in preparation for a marketing application. It provides confirmation that the Committee for Advanced Therapies (CAT), recognizes that the C-Cure® development program continues to meet the rigorous standards set by the EMA for a successful development and submission package. Also in April, Celyad announced the appointment of 10 leading international Immuno-Oncology experts to its Scientific Advisory Board in order to develop its NKR-T platform and potentially open the path to new treatment options for cancer patients. (Dr. Hinrich Abken, Dr. Scott Antonia, Dr. Marco Davila, Dr. Stéphane Depil, Dr. Marc Ernstoff, Dr. David Edward Gilham, Dr. Sebastian Kobold, Dr. Daniel Olive, Dr. Charles Sentman and Dr. Jeffrey S. Weber).
“We now look forward to the expected announcement of the topline data from our CHART-1 Phase III trial and the safety and feasibility data on the first doses in our NKR-2 Phase I/IIa study at the end of June.” Dus Mid 2016 is echt Mid 2016 ;-)
Goed goed. Nog 6 weekjes.
€44 dat gaat richting en mogelijk bijkoop moment. Helaas wordt het algemene sentiment er niet beter op. Ook de biotech (NBI weer onder de 2700) staat weer onder druk.
Ik wacht nog even aan de zijlijn. Maar zorg wel dat ik voor juni er weer in zit.
Zo gaat dat schreef op 19 mei 2016 20:58 :
Ik wacht nog even aan de zijlijn. Maar zorg wel dat ik voor juni er weer in zit.
Je hebt gelijk. Herstelletje vandaag maar nasdaq gaat even diep in de min. De correlatie tussen koers VS en EU is voor mij een raadsel. Maar goed soit. Nog 5 weken.
Neem mei: de helft van het de handelsdagen zijn de uitslagen aanzienlijk > 1% Aan volatiliteit geen gebrek...
Voorlopig al 65 hele stukken verhandeld op de Nasdaq. Koers onveranderd.
Celyad successfully completes safety follow-up of the third dose level of its NKR-2 Trial * The trial is a dose escalation study evaluating safety and feasibility of NKR-2 T-cell therapy in patients with Acute Myeloid Leukemia or Multiple Myeloma. * No dose limiting toxicity reported in the last patient of the third dose level. * Process to enroll the first patient of fourth dose cohort has commenced.Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the completion of the 21-day safety follow-up of the last patient enrolled in the third dose level cohort in its Phase I/IIa clinical trial evaluating the safety and feasibility of its NKR-2 T-cell therapy using T-cells with NKG2D receptor in Acute Myeloid Leukemia and Multiple Myeloma patients. No safety issues were reported.Dr. Christian Homsy, CEO of Celyad: “The study is progressing as planned, with the third dose level successfully completed and the upcoming initiation of the fourth dose level cohort, and no adverse safety signals observed so far for the 9 treated patients. We are now preparing the next dose levels and look forward to the data that are expected in the next few months.”Dr. Frédéric Lehmann, Head of Immuno-Oncology at Celyad: “We are pleased that no adverse safety signal has been reported for the patients of the third dose of this first-in-human Phase I/IIa study. This technology has great potential in multiple cancer indications and we look forward to completing this Phase I/IIa and moving to the next stage of our clinical development. I am grateful to our principal investigator who has positioned us so well to complete the fourth dose by mid-2016.”About Celyad’s NKR-T program NKR stands for Natural Killer Receptor. NKG2D CAR T-cells are now called NKR-2 T-cells and the product development name is NKR-2. Existing CAR-T cells are engineered using constructs encoding an antibody single chain variable fragment, the signaling domain of CD3 zeta and one or more co-stimulatory domain(s). In contrast to existing CAR-T cells, Celyad’s lead immuno-oncology product candidate, NKR-2, is a T-Cell encoded to express the human Natural Killer activating receptor, NKG2D. Using the human Natural Killer cell receptor, unlike traditional CAR technologies, has the potential to: * Bind to 8 different ligands that are expressed by a vast majority of cancer cells, both hemaetological and solid malignancies. * Target and kill tumors as well as the blood vessels that feed them and also express the ligands of the NKG2D receptor. * Target and kill the inhibitory mechanisms preventing the tumor from evading the immune system. * Induces adaptive auto-immune response thanks to the creation of a long term cell memory against the targeted tumor. The research underlying this technology was originally conducted by Dartmouth College Professor Charles Sentman, and has been published in numerous peer-reviewed publications. NKR-2 has an active Investigational New Drug (IND) application with the FDA for a Phase I clinical trial. The full data readout from the Phase I dose escalation trial is expected in mid-2016. The trial is designed to assess the safety and feasibility of NKR-2 in acute myeloid leukemia and multiple myeloma patients, with secondary endpoints including clinical activity.The safety follow-up period post-infusion has been decreased to 21 days after approval by the U.S. Food and Drug Administration (FDA) and Institutional Review Board (IRB).
Op dit slappe dagje toch maar weer gedeeltelijk ingestapt. Koers blijft goed liggen rond 45,50 en ik wil slag eind juni bij afronding Phase III niet missen. Bij positieve resultaten moeten 50+ koersen haalbaar zijn.
Zo gaat dat schreef op 27 mei 2016 13:11 :
Op dit slappe dagje toch maar weer gedeeltelijk ingestapt. Koers blijft goed liggen rond 45,50 en ik wil slag eind juni bij afronding Phase III niet missen. Bij positieve resultaten moeten 50+ koersen haalbaar zijn.
Idem. Nog 5 weken.
Zit een beetje met dat koersdoel van KBC ....wat is hun motivatie. Nb we staan al op 46.
Na recente koersstijging Galapagos nu posities wat afbouwen en richting eind juni langzaam posities in Celyad uitbreiden. N.B. Geen zorgen over KBC. Analist Jan de Kerpel is erg conservatief met zijn koersdoelen.
Ik sprokkel op de dips... De kerpel zit er vaak naast en ook soms te hoog: tig, Mdx, thrombogenics... Met ablynx en Celyad zit hij te laag imho.
Natte krant en Dr Bob denken jullie dat Celyad meer en harder gaat stijgen dan Glpg, zo ja waarom dan.
tonneke schreef op 27 mei 2016 23:56 :
Natte krant en Dr Bob denken jullie dat Celyad meer en harder gaat stijgen dan Glpg, zo ja waarom dan.
Nee dat ik niet Tonneke. Eind juni worden resultaten bekendgemaakt. In aanloop naar die datum zou de koers kunnen oplopen mogelijk 5-10%. Zijn de resultaten goed dan zal dat wel weer wat consolidatie geven. Zie je bij gala ook. Is er minder goed nieuws dan weet je het wel. Het is biotech. Dan is het horror. Ik verwacht goed nieuws.
Hoi Tonneke, Zelf zit ik verhoudingsgewijs zeer dik in GALA en dit houd ik ook zo. Wel verwacht ik voor Celyad een forse stijging als Fase III resultaten positief zijn. De berichten die tot nu toe naar buiten zijn gekomen, laten een gedegen beeld zien van het bedrijf. Celyad blijft ook een zeer volatiel aandeel, die zich lastig laat lezen en waarover (naar mijn mening) relatief weinig informatie op internet te vinden is. Hierdoor houd ik mijn investeringen in Celyad beperkt. Omdat nu binnen een paar weken de resultaten bekend worden, heb ik een deel van mijn Tigenix aandelen verruild voor Celyad.
CYAD heeft veel korte termijn stijgingspotentieel. Eerst door de grens van 50 euro en dan minimaal een stijging tot 60 euro, maar wellicht 70 euro.
Dr. Bob schreef op 30 mei 2016 10:34 :
CYAD heeft veel korte termijn stijgingspotentieel. Eerst door de grens van 50 euro en dan minimaal een stijging tot 60 euro, maar wellicht 70 euro.
Wel vandaag is al weer een voorbeeld dat de druk opwaarts is..
Het beslechten van de 50 euro grens lijkt een kwestie van dagen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee